Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer: Crizotinib resistance in ALK NSCLC

Background ALK‐tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK‐positive non‐small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better prognosis.